Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Michael Palese"'
Publikováno v:
Clinical Genitourinary Cancer. 17:e1011-e1019
Introduction The objective of this study was to assess the impact of volume status on socio-demographic disparities for radical prostatectomy (RP) in New York State. Patients and Methods All patients undergoing RP from 2006 to 2014 with an admitting
Autor:
Dimple Chakravarty, Parita Ratnani, Michael Palese, Ashutosh K. Tewari, Ivan Jambor, Nir Tomer, Zachary Dovey, Nihal Mohamed
Publikováno v:
Prostate cancer and prostatic diseases. 25(4)
INTRODUCTION Prostate cancer (PCa) is a heterogenous disease with multiple etiological factors playing a role in its development. Recently, chronic and systemic inflammatory conditions such as inflammatory bowel disease were identified as key risk fa
Autor:
Ketan K. Badani, Michael Palese, Aaron M. Fischman, Colton Welch, Reza Mehrazin, John J. Griffith, Zeynep Gul
Publikováno v:
Urology. 125:118-122
Objective To evaluate outcomes after focal ablative therapy for renal cell carcinoma (RCC) in transplant allograft kidneys. Methods After institutional review board approval, patients with a history of RCC in a transplanted allograft kidney who under
Autor:
Avinash Reddy, Krishna Ravivarapu, Devki Shukla, Steven A. Kaplan, Michael Palese, Alexander C. Small, Evan Garden
Publikováno v:
World Journal of Urology
Purpose Rezum is a minimally invasive surgery for benign prostatic hyperplasia. Current guidelines recommend Rezum for prostates
Publikováno v:
Urology. 103:117-123
Objective To compare utilization trends and short-term outcomes of robotic versus open radical cystectomy for bladder cancer since the introduction of the robotic modifier (ICD-9 17.4x). Materials and Methods Using the Statewide Planning and Research
Publikováno v:
Journal of Robotic Surgery. 11:223-229
The aim of the study was to compare the utilization trends and short-term outcomes of open, laparoscopic, and robotic partial nephrectomy in New York State since the introduction of the robotic modifier in October 2008. The Statewide Planning and Res
Publikováno v:
Urologic oncology. 35(6)
Objective To determine the effect of frailty on patient outcomes including any complication, Clavien-Dindo IV (CDIV) (intensive care unit-level) complications, and 30-day mortality for robotic-assisted radical prostatectomies (RARP) patients in compa
Autor:
Benjamin A. Gartrell, William Oh, Juan P. Wisnivesky, James Godbold, Simon J. Hall, Erin Moshier, Matthew D. Galsky, Michael Palese, Guru Sonpavde, Max Kates, Che-Kai Tsao, Alexander C. Small
Publikováno v:
World Journal of Urology. 31:1535-1539
Two randomized trials published in 2001 provided level 1 evidence for the use of cytoreductive nephrectomy (CyNx) for the treatment of metastatic renal cell carcinoma (mRCC). However, the regulatory approval of vascular endothelial growth factor tyro
Autor:
Che-Kai Tsao, James Godbold, Michael Palese, Alexander C. Small, William Oh, Guru Sonpavde, Matthew D. Galsky, Simon J. Hall, Benjamin A. Gartrell, Juan P. Wisnivesky, Erin Moshier
Publikováno v:
Clinical Genitourinary Cancer. 10:159-163
Two randomized trials published in 2001 established CyNx for patients with metastatic renal carcinoma (mRCC) as a treatment standard in the cytokine era. However, first-line systemic therapy for mRCC changed in 2005 with FDA approval of VEGFR TKIs. W
Publikováno v:
Urology. 98
Objective To elucidate the evolving trends in subspecialization related to individual practice within inpatient urology over a 31-year period spanning from 1982 to 2012. Methods We conducted a retrospective cohort study by querying the centralized Ne